SCHEMBL25758644

SCHEMBL25758644

COc1ccc(NC(=O)c2cn(C)c3ncccc23)cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MAPT P10636 5/20 0.51
GAA P10253 3/20 0.49
POLB P06746 1/20 0.49
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
IDH1 O75874 2/20 0.47
ALPL P05186 2/20 0.46
CPT2 P23786 1/20 0.46
CPT1A P50416 1/20 0.46
ALDH1A1 P00352 2/20 0.46
ALOX12 P18054 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
GRM4 Q14833 1/20 0.46
KCNJ1 P48048 1/20 0.46
KCNH2 Q12809 1/20 0.46
KDM4E B2RXH2 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23846447 0.91 MAPT (0.46) LMNASMN1; SMN2MAPTGAAPOLB
SCHEMBL30150995 0.88 MAPT (0.46) LMNASMN1; SMN2MAPTGAAPOLB
SCHEMBL23833490 0.88 MAPT (0.46) LMNASMN1; SMN2MAPTGAAPOLB
SCHEMBL25754534 0.88 MEN1 (0.49) LMNASMN1; SMN2MAPTGAAPOLB
SCHEMBL23840486 0.79 IDH1 (0.40) MAPTGAAPOLBMEN1KMT2A
SCHEMBL23833429 0.75 HTR2C (0.43) MAPTGAAPOLBMEN1KMT2A
SCHEMBL30151060 0.75 HTR2C (0.43) MAPTGAAPOLBMEN1KMT2A
SCHEMBL25757369 0.75 LMNA (0.54) LMNASMN1; SMN2MAPTGAAPOLB
SCHEMBL25758942 0.75 LMNA (0.59) LMNASMN1; SMN2MAPTGAAMEN1
SCHEMBL30199798 0.74 LMNA (0.53) LMNASMN1; SMN2MAPTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 LMNA 3435/4885SMN1; SMN2 405/4885MAPT 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.